Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21412998 | 0.79 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL19997380 | 0.77 | WNT3A (0.44) | TRPA1PORCN | |
| SCHEMBL21935695 | 0.77 | PORCN (0.46) | TRPA1TRPV4TP53RXFP1SMN1; SMN2 | |
| SCHEMBL19590943 | 0.77 | GAA (0.45) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL23416909 | 0.76 | PORCN (0.58) | TRPA1PORCN | |
| SCHEMBL19626366 | 0.76 | PORCN (0.42) | TRPA1TRPV4PORCN | |
| SCHEMBL21412993 | 0.76 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL19590966 | 0.75 | ALDH1A1 (0.51) | MAPTTP53POLBTHRBKMT2A | |
| SCHEMBL22085071 | 0.74 | SMN1; SMN2 (0.46) | RXFP1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23416897 | 0.74 | CYP1A2 (0.42) | TRPA1TRPV4MAPTRXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPA1, TRPV1, TRPV2 | GRM5 411/4885TRPA1 1/4885YTHDC1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.